| SFDA Approved Use |
PACLITAXEL KABI is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, PACLITAXEL KABI is indicated in combination with cisplatin.
PACLITAXEL KABI is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. PACLITAXEL KABI is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. PACLITAXEL KABI in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. PACLITAXEL KABI is indicated for the second-line treatment of AIDS- related Kaposi’s sarcoma. |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.